DOCSLIB.ORG

Association Between Use of Desloratadine and Risk of Seizures, Supraventricular Tachycardia, and Atrial Fibrillation Or Flutter: a Nordic Register-Based Study

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Association Between Use of Desloratadine and Risk of Seizures, Supraventricular Tachycardia, and Atrial Fibrillation Or Flutter: a Nordic Register-Based Study DESLORATADINE PAGE 1 EPIDEMIOLOGY NO.: EP07044.002 PROTOCOL NO/AMENDMENT NO.: MK-4117-203 EU PAS REGISTER NO./EUDRACT NO.: 15038 Association between use of desloratadine and risk of seizures, supraventricular tachycardia, and atrial fibrillation or flutter: A Nordic register-based study (EU GUIDANCE: 23 JANUARY 2013 EMA/738724/2012) 05822K DESLORATADINE P A G E 2 EPI DE MI OL O G Y N O.: EP 07044.002 PROTOCOL NO/A MEND MEN T N O.: M K -4117 -2 0 3 E U P AS RE GISTE R N O./ EUDRACT NO .: 15038 PASS INF OR MATI ON Titl e Ass o ci ati o n b et w een use of desloratadine and risk of seizures, s u pr a v e ntri c ul ar t a c h y c ar di a, a n d atri al fi brill ati o n or fl utt er: A N or di c r e gist er -based study V e rsi o n i d e ntifi e r of t h e 1 fi nal st u dy re port Date of last versio n of t he 1 0 May 2019 fi nal st u dy re port E U P AS register nu mber E UP AS15038 Active s u bsta nce Desloratadine, A T C code R06 A X27; Phar macotherapeutic group: A nti hist a mi n es – H 1 a nt a g o nist Medicinal product A E RI US, AZ O M YR, and NE OCL ARIT Y N Product reference E U/ 1/ 0 0/ 1 6 0, A E RI U S E U/ 1/ 0 0/ 1 5 7, A Z O M Y R E U/1/00/161, NE OCL ARIT Y N Procedure nu mber E ME A/ H/ C/000313/ ME A/065, AE RI US E ME A/ H/C/000310/ ME A/065, AZ O M YR E ME A/ H/C/000314/ ME A/065, NE OCL ARIT Y N Marketing authorisation Merck Sharp & Doh me B. V. hol der(s) Waarder w e g 3 9 2031 B N Haarle m The Netherlands Joint P ASS N o Research question and T o d es cri b e t h e us e of d esl or at a di n e i n t h e g e n er al p o p ul ati o n; t o o bjectives describe the incidence rates of first seizure, supraventricular t a c h y c ar di a, atri al fi brill ati o n or fl utt er , a n d first r e c urr e nt s ei z ur e; and to exa mine the associations bet ween desloratadine exposure a n d ris k of first s ei z ur e, s u pr a v e ntri c ul ar t a c h y c ar di a, atri al fi brill ati o n or fl utt er, a n d first r e c urr e nt s ei z ur e. Co u ntry( -ies) of st u dy D e n m ar k, Fi nl a n d, and S weden A ut hor A n n ett e Kj ær Ers b øll P P D of S o ut h er n D en mark St u di estr æ d e 6 D K -1 4 5 5 Copenhagen K Den mark P h o n e: P P D E -ma il: P P D Merck Final Repository 1 0 -J U N -2019 ( R C A M) Date (E U G UI D A NCE: 23 J A N U AR Y 2013 E M A/738724/2012) 05822 K DESLORATADINE P A G E 3 EPI DE MI OL O G Y N O.: EP 07044.002 PROTOCOL NO/A MEND MEN T N O.: M K -4117 -2 0 3 E U P AS RE GISTE R N O./ EUDRACT NO .: 15038 MAR KETIN G AUTHORISATION HOLDER ( S) M ar k eti n g a ut h oris ati o n Merck Sharp & Doh me B. V. h ol der(s) Waarder w e g 3 9 2031 B N Haarle m The Netherlands M A H contact person P P D Gl o b al R e g ul at or y Aff airs – R AI E M E A R e gi o n al Center Merck Sharp & Doh me ( Europe), I n c. Lynx Binnenhof 5 1200 Brussels, Belgiu m P h o n e: P P D F a x: P P D E -ma il: P P D (E U G UI D A NCE: 23 J A N U AR Y 2013 E M A/738724/2012) 05822 K DESLORATADINE PAGE 4 EPIDEMIOLOGY NO.: EP07044.002 PROTOCOL NO/AMENDMENT NO.: 4117-203 EU PAS REGISTER NO./EUDRACT NO.: 15038 text TABLE OF CONTENTS TABLE OF CONTENTS .............................................................................................. 4 LIST OF TABLES ......................................................................................................... 7 LIST OF FIGURES ....................................................................................................... 8 LIST OF ANNEXES...................................................................................................... 9 1 ABSTRACT................................................................................................................. 10 2 LIST OF ABBREVIATIONS .................................................................................... 14 3 INVESTIGATORS ..................................................................................................... 15 4 OTHER RESPONSIBLE PARTIES......................................................................... 15 5 MILESTONES ............................................................................................................ 16 6 RATIONALE AND BACKGROUND ...................................................................... 17 7 RESEARCH QUESTION AND OBJECTIVES ...................................................... 17 8 AMENDMENTS AND UPDATES............................................................................ 18 9 RESEARCH METHODS........................................................................................... 18 9.1 Study design.............................................................................................................. 18 9.2 Setting........................................................................................................................ 21 9.3 Subjects ..................................................................................................................... 21 9.4 Variables ................................................................................................................... 24 9.4.1 Exposure ................................................................................................................. 24 9.4.2 Outcome.................................................................................................................. 26 9.4.3 Covariates ............................................................................................................... 27 9.4.4 Other variables........................................................................................................ 31 9.5 Data sources and measurement .............................................................................. 31 9.5.1 Study Procedures .................................................................................................... 32 9.6 Bias ............................................................................................................................ 33 9.7 Study size .................................................................................................................. 36 9.7.1 Fixed sample size.................................................................................................... 36 9.7.2 Proportion of current and non-current exposure time among DL users for the purpose of calculation of minimum detectable IRR ................................................. 36 9.7.3 Background event rate ............................................................................................ 37 9.7.4 Number of years in the study.................................................................................. 37 (EU GUIDANCE: 23 JANUARY 2013 EMA/738724/2012) 05822K DESLORATADINE PAGE 5 EPIDEMIOLOGY NO.: EP07044.002 PROTOCOL NO/AMENDMENT NO.: 4117-203 EU PAS REGISTER NO./EUDRACT NO.: 15038 text 9.7.5 Statistical parameters and assumptions................................................................... 38 9.7.6 Example of calculating the minimum detectable IRR ............................................ 38 9.8 Data transformation ................................................................................................ 39 9.8.1 Data management.................................................................................................... 40 9.9 Statistical methods ................................................................................................... 42 9.9.1 Main summary measures ........................................................................................ 42 9.9.2 Main statistical methods ......................................................................................... 42 9.9.2.1 Substudy 1: Descriptive analysis of exposure of DL........................................... 42 9.9.2.2 Substudy 2: First seizure...................................................................................... 43 9.9.2.3 Substudy 3: SVT.................................................................................................. 43 9.9.2.4 Substudy 4: Atrial fibrillation/flutter ................................................................... 44 9.9.2.5 Substudy 5: First recurrent seizure ...................................................................... 45 9.9.2.6 Additional information for Substudies 2A, 3A, 4A, and 5A ............................... 45 9.9.2.7 Additional information for Substudies 2B, 3B, 4B, and 5B ................................ 46 9.9.3 Missing values ........................................................................................................ 46 9.9.4 Sensitivity analyses................................................................................................. 47 9.9.5 Post hoc analyses .................................................................................................... 56 9.9.6 Amendments to the statistical analysis plan ........................................................... 57 9.10 Quality control ....................................................................................................... 58 10 RESULTS .................................................................................................................. 59 10.1 Participants............................................................................................................. 59 10.1.1 Protection of Human Subjects .............................................................................. 59 10.2 Descriptive data.....................................................................................................
Load more

Recommended publications
  • Potential Drug-Drug Interactions and Adverse Drug Reactions Associated with Hydroxychloroquine
    Original Article Potential Drug-drug Interactions and Adverse Drug Reactions Associated with Hydroxychloroquine Arjun Singh1, Richa Chaudhary1, Prayas Verma2, Nilanchal Trivedi3,*, Md. Shamim4 1Department of Pharmacy Practice, Teerthanker Mahaveer College of Pharmacy, TMU, Moradabad, Uttar Pradesh, INDIA. 2Teerthanker Mahaveer Dental College and Research Centre, TMU Moradabad, Uttar Pradesh, INDIA. 3Department of Pharmacology, Teerthanker Mahaveer College of Pharmacy, TMU, Moradabad, Uttar Pradesh, INDIA. 4LCP College of Pharmacy Baghpat, Abdul Kalam Technical University (AKTU), Uttar Pradesh, INDIA. ABSTRACT Introduction: COVID-19 is a pandemic disaster and a health emergency of prime focus for all the world economies. Various prophylactic treatments are considered to combat the disease. Hydroxychloroquine drug is one such option that is given much attention as an armor against SARS COV-2 pandemic. Evaluation and assessment of drug interactions and ADRs is required from ethical concern to justify the use of HCQ on such large scale. Methods: We have performed an analysis of HCQ drug interactions on Micromedex®. We have reviewed literature of HCQ pharmacokinetic properties, ADRs/ ADEs and toxicities associated with the use of HCQ drug on PubMed, Google Scholar and CDC database. Results: There are around 180 drug interactions possible with HCQ. Out of them 13 are of contraindicated severity level and other 165 are of major severity and 2 of them are moderately severe. Most of the interactions are coupled with QT prolonging agents (170), Cardiac arrhythmias is possible with the concomitant use of at least 2 drugs, 4 drugs leads to Torsade de points. System organ level ADRs are also evaluated along with various precautions, warnings and contraindications.
    [Show full text]
  • Urticaria: Current Opinions About Etiology, Diagnosis and Therapy
    Acta Derm Venereol 2007; 87: 196–205 REVIEW ARTICLE Urticaria: Current Opinions about Etiology, Diagnosis and Therapy Torsten ZUBERBIER and Marcus MAURER Department of Dermatology and Allergy, Allergie-Centrum-Charité, Charité – Universitätsmedizin, Berlin, Germany In the last few decades an increasing understanding of British Association of Dermatologists (4) and the most the pathomechanisms involved in urticaria has highlight­ recent European Academy of Allergology and Clinical ed the heterogeneity of different subtypes. According to Immunology/Global Allergy and Asthma European Net- the new European Academy of Allergology and Clinical work/European Dermatology Forum (EAACI/GA²LEN/ Immunology/Global Allergy and Asthma European Net­ EDF) guidelines. For preparing the latter, more than work/European Dermatology Forum (EAACI/GA²LEN/ 300 specialists from over 15 countries held a consensus EDF) guidelines, urticaria subtypes can be grouped into meeting regarding the definition, classification, routine spontaneous urticaria, which includes acute urticaria diagnosis and management of urticaria. Evidence-ba- and chronic urticaria, the physical urticarias, and other sed suggestions, prepared by a panel in advance, were urticaria disorders, including, for example, contact ur­ discussed using a voting system (5, 6). ticaria. Clarity of nomenclature is required not only to Due to the heterogeneity of the disease, the interpre- choose the correct measures in diagnosis and manage­ tation of divergent data from different centres regarding ment, but also to compare data from different studies. eliciting causes in subtypes of urticaria and their therapeu- Urticaria has a profound impact on quality of life and tic responsiveness is, however, sometimes difficult, as the performance. Effective treatment is thus required in all influence of different study populations is considerable.
    [Show full text]
  • Antihistamines in the Treatment of Chronic Urticaria I Jáuregui,1 M Ferrer,2 J Montoro,3 I Dávila,4 J Bartra,5 a Del Cuvillo,6 J Mullol,7 J Sastre,8 a Valero5
    Antihistamines in the treatment of chronic urticaria I Jáuregui,1 M Ferrer,2 J Montoro,3 I Dávila,4 J Bartra,5 A del Cuvillo,6 J Mullol,7 J Sastre,8 A Valero5 1 Service of Allergy, Hospital de Basurto, Bilbao, Spain 2 Department of Allergology, Clínica Universitaria de Navarra, Pamplona, Spain 3 Allergy Unit, Hospital La Plana, Villarreal (Castellón), Spain 4 Service of Immunoallergy, Hospital Clínico, Salamanca, Spain 5 Allergy Unit, Service of Pneumology and Respiratory Allergy, Hospital Clínic (ICT), Barcelona, Spain 6 Clínica Dr. Lobatón, Cádiz, Spain 7 Rhinology Unit, ENT Service (ICEMEQ), Hospital Clínic, Barcelona, Spain 8 Service of Allergy, Fundación Jiménez Díaz, Madrid, Spain ■ Summary Chronic urticaria is highly prevalent in the general population, and while there are multiple treatments for the disorder, the results obtained are not completely satisfactory. The second-generation H1 antihistamines remain the symptomatic treatment option of choice. Depending on the different pharmacokinetics and H1 receptor affi nity of each drug substance, different concentrations in skin can be expected, together with different effi cacy in relation to the histamine-induced wheal inhibition test - though this does not necessarily have repercussions upon clinical response. The antiinfl ammatory properties of the H1 antihistamines could be of relevance in chronic urticaria, though it is not clear to what degree they infl uence the fi nal therapeutic result. Before moving on to another therapeutic level, the advisability of antihistamine dose escalation should be considered, involving increments even above those approved in the Summary of Product Characteristics. Physical urticaria, when manifesting isolatedly, tends to respond well to H1 antihistamines, with the exception of genuine solar urticaria and delayed pressure urticaria.
    [Show full text]
  • Association of Pediatric Atopic Dermatitis and Cataract Development and Surgery
    Supplementary Online Content Jeon HS, Choi M, Byun SJ, Hyon JY, Park KH, Park SJ. Association of pediatric atopic dermatitis and cataract development and surgery. JAMA Ophthamol. Published online June 7, 2018. doi:10.1001/jamaophthalmol.2018.2166 eTable 1. List of diagnostic codes used for defining subjects eTable 2. Drug lists used for defining atopic dermatitis eTable 3. Baseline characteristics of atopic dermatitis cohort and control group eTable 4. Cox analysis-derived hazard ratios (HRs) and 95% confidence intervals (CIs) of cataract development associated with atopic dermatitis (AD) and its covariates eTable 5. Cox analysis-derived hazard ratios (HRs) and 95% confidence intervals (CIs) of cataract surgery associated with atopic dermatitis (AD) and its covariates This supplementary material has been provided by the authors to give readers additional information about their work. © 2018 American Medical Association. All rights reserved. Downloaded From: https://jamanetwork.com/ on 09/24/2021 eTable 1. List of diagnostic codes used for defining subjects Diagnoses Code numbers in KCD-6a Atopic dermatitis L20 Cataract H25, H26 Congenital malformation of eyes (anopthalmos, microphthalmos, and Q11 macrophthalmos) Congenital lens malformation Q12 Congenital malformation of anterior segment of eyes Q13 Congenital malformation of posterior segment of eyes Q14 Other congenital malformations of eyes Q15 Cataract surgery S5110, S5111, S5112, S5119 Asthma J45.0, J45.9 Allergic rhinitis J30.1, J30.2, J30.3, J30.4 aThe diagnosis was coded according to the Korean Classification of Disease, 6th edition (KCD-6, a version of the International Classification of Diseases, 10th edition, adapted for the Korean healthcare system). © 2018 American Medical Association.
    [Show full text]
  • H1-Antihistamines for Chronic Spontaneous Urticaria Sharma, M., Bennett, C., Cohen, S,N
    H1-antihistamines for chronic spontaneous urticaria Sharma, M., Bennett, C., Cohen, S,N. and Carter, B. Published version deposited in CURVE November 2015 Original citation & hyperlink: Sharma, M., Bennett, C., Cohen, S,N. and Carter, B. (2014) H1-antihistamines for chronic spontaneous urticaria. Cochrane Database of Systematic Reviews, volume 2014 (11): Article number CD006137. http://dx.doi.org/10.1002/14651858.CD006137.pub2 Copyright © and Moral Rights are retained by the author(s) and/ or other copyright owners. A copy can be downloaded for personal non-commercial research or study, without prior permission or charge. This item cannot be reproduced or quoted extensively from without first obtaining permission in writing from the copyright holder(s). The content must not be changed in any way or sold commercially in any format or medium without the formal permission of the copyright holders. CURVE is the Institutional Repository for Coventry University http://curve.coventry.ac.uk/open H1-antihistamines for chronic spontaneous urticaria (Review) Sharma M, Bennett C, Cohen SN, Carter B This is a reprint of a Cochrane review, prepared and maintained by The Cochrane Collaboration and published in The Cochrane Library 2014, Issue 11 http://www.thecochranelibrary.com H1-antihistamines for chronic spontaneous urticaria (Review) Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd. TABLE OF CONTENTS HEADER....................................... 1 ABSTRACT ...................................... 1 PLAINLANGUAGESUMMARY
    [Show full text]
  • Patent Application Publication ( 10 ) Pub . No . : US 2019 / 0192440 A1
    US 20190192440A1 (19 ) United States (12 ) Patent Application Publication ( 10) Pub . No. : US 2019 /0192440 A1 LI (43 ) Pub . Date : Jun . 27 , 2019 ( 54 ) ORAL DRUG DOSAGE FORM COMPRISING Publication Classification DRUG IN THE FORM OF NANOPARTICLES (51 ) Int . CI. A61K 9 / 20 (2006 .01 ) ( 71 ) Applicant: Triastek , Inc. , Nanjing ( CN ) A61K 9 /00 ( 2006 . 01) A61K 31/ 192 ( 2006 .01 ) (72 ) Inventor : Xiaoling LI , Dublin , CA (US ) A61K 9 / 24 ( 2006 .01 ) ( 52 ) U . S . CI. ( 21 ) Appl. No. : 16 /289 ,499 CPC . .. .. A61K 9 /2031 (2013 . 01 ) ; A61K 9 /0065 ( 22 ) Filed : Feb . 28 , 2019 (2013 .01 ) ; A61K 9 / 209 ( 2013 .01 ) ; A61K 9 /2027 ( 2013 .01 ) ; A61K 31/ 192 ( 2013. 01 ) ; Related U . S . Application Data A61K 9 /2072 ( 2013 .01 ) (63 ) Continuation of application No. 16 /028 ,305 , filed on Jul. 5 , 2018 , now Pat . No . 10 , 258 ,575 , which is a (57 ) ABSTRACT continuation of application No . 15 / 173 ,596 , filed on The present disclosure provides a stable solid pharmaceuti Jun . 3 , 2016 . cal dosage form for oral administration . The dosage form (60 ) Provisional application No . 62 /313 ,092 , filed on Mar. includes a substrate that forms at least one compartment and 24 , 2016 , provisional application No . 62 / 296 , 087 , a drug content loaded into the compartment. The dosage filed on Feb . 17 , 2016 , provisional application No . form is so designed that the active pharmaceutical ingredient 62 / 170, 645 , filed on Jun . 3 , 2015 . of the drug content is released in a controlled manner. Patent Application Publication Jun . 27 , 2019 Sheet 1 of 20 US 2019 /0192440 A1 FIG .
    [Show full text]
  • Assessment of the Anticholinergic Effect of the New Antihistamine Mizolastine in Healthy Subjects
    Br. J. clin. Pharmac. (1992), 34, 328-331 Assessment of the anticholinergic effect of the new antihistamine mizolastine in healthy subjects P. DANJOU', P. MOLINIER2, I. BERLIN2, A. PATAT1, P. ROSENZWEIG' & P. L. MORSELLI1 1Synthelabo Recherche (LERS), Department of Clinical Research, 31 avenue Paul Vaillant-Couturier, 92225 Bagneux and 2Therapharm Recherches, 59 rue de Billancourt, 92100 Boulogne, France 1 Twelve healthy subjects were enrolled in a double-blind placebo controlled cross-over study in order to assess the possible anticholinergic effects of four doses of a new antihistamine compound, mizolastine, compared with hyoscine butylbromide (HBB) used as a reference anticholinergic drug. 2 Although mizolastine, a potent and selective Hl-receptor blocker has no affinity for muscarinic receptors and does not antagonize the effects of carbachol in rodents, a study was initiated to investigate its effects on various effectors possessing muscarinic receptors (eye, heart, sweat gland, salivary gland). 3 HBB (40 mg, s.c.) impaired accommodation, decreased salivary flow and inhibited cardiac sinus arrhythmia. Pupil diameter and maximum constriction speed, carbachol- induced skin sweating and Valsalva ratio were unaffected. 4 Mizolastine (5, 10, 20, 40 mg p.o.) did not affect any parameter at any time point, demonstrating a lack of anticholinergic effect. Keywords antihistamine mizolastine anticholinergic hyoscine butylbromide autonomic nervous system salivation pupil-size Introduction While the first generation promethazine-related, cholinergic activity since its polar structure does not H1-receptor blockers possess anticholinergic activity allow the drug readily to cross the blood to brain barrier. and sedative effects, the second generation of specific H1-receptor antihistamines (e.g. terfenadine (Vargas et al., 1989)) show a better tolerability with less effects on CNS function and are devoid of anticholinergic effects.
    [Show full text]
  • Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued
    20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0
    [Show full text]
  • Use of Combinations Comprising Non-Sedating Antihistamines And
    Europaisches Patentamt (19) European Patent Office Office europeen des brevets (11) EP 0 903 151 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) int. CI 6: A61 K 45/06, A61K 31/55, 24.03.1999 Bulletin 1999/12 A61K 31/415 (21) Application number: 97116494.2 //(A61K31/55, 31:415) (22) Date of filing: 22.09.1997 (84) Designated Contracting States: (72) Inventors: AT BE CH DE DK ES Fl FR GB GR IE IT LI LU MC • Dr. Diez Crespo, Maria del Carmen NL PT SE 28043 Madrid (ES) Designated Extension States: • Dr.Mainardi, Roberto AL LT LV RO SI 05101-070 Sao Paulo - SP (BR) • Prof. Szelenyi, Istvan (71) Applicant: D-90571 Schwaig (DE) ASTA Medica Aktiengesellschaft • Dr. Muckenschnabel, Reinhard D-01 277 Dresden (DE) D-60388 Frankfurt (DE) (54) Use of combinations comprising non-sedating antihistamines and alpha-adrenergic drugs for the topical treatment of rhinitis/conjunctivitis and cold, cold-like and/or flu symptoms (57) Pharmaceutical combination, applicable topi- cally, containing a non-sedating antihistamine in combi- nation with an a-adrenergic agonist and optionally conventional physiologically acceptable carriers, dilut- ing agents and auxiliaries substances for the prophy- laxis and treatment of allergic and/or vasomotoric rhinitis, conjunctivitis, cold, cold-like and/ or flu symp- toms are claimed. < LO CO o o Q_ LU Printed by Xerox (UK) Business Services 2.16.7/3.6 EP 0 903 151 A1 Description Technical field 5 [0001] The present invention relates generally to novel pharmaceutical compositions containing ..topical decongest- ants", preferably epinephrine, fenoxazoline, indanazoline, naphazoline, oxedrine, oxymetazoline, phenylephrine, tefazo- line, tetryzoline, tramazoline, tymazoline or xylometazoline and a non-sedating antihistamine, applicable topically such as levocabastine, ef letirizine, however preferably azelastine.
    [Show full text]
  • Antihistamines and Driving-Related Behavior: a Review of the Evidence for Impairment by First- Versus Second-Generation H1-Antagonists
    DOT HS 809 714 May 2004 Technical Report Documentation Page 1. Report No. 2. Government Accession No. 3. Recipient's Catalog No. DOT HS 809 714 4. Title and Subtitle 5. Report Date ANTIHISTAMINES AND DRIVING-RELATED BEHAVIOR: May 2004 A REVIEW OF THE EVIDENCE FOR IMPAIRMENT 6. Performing Organization Code 7. Author(s) 8. Performing Organization Report No. Herbert Moskowitz, Ph.D. and Candace Jeavons Wilkinson, Ph.D. 9. Performing Organization Name and Address 10. Work Unit No. (TRAIS) Herbert Moskowitz, Ph.D., Inc. 11. Contract or Grant No. 4138 Royal Crest Place, Encino, CA 91436 12. Sponsoring Agency Name and Address’ 13. Type of Report and Period Covered U.S. Department of Transportation Final Report National Highway Traffic Safety Administration Period: September 2000-February 2003 400 Seventh Street, S.W Washington, D.C. 20590 14. Sponsoring Agency Code 15. Supplementary Notes 16. Abstract A review of the scientific literature concerning the effects of antihistamines on driving-related skills was conducted. After reviewing all pertinent publications from 1998 and earlier, a total of 130 publications were found to meet criteria for inclusion in the data summaries. A data base was created with study results being indexed, and summarized, by specific drug, dose, dosing schedule (i.e., single versus repeated) and H1-antagonist generation as well as by behavioral area or subjective measure. For each H1-antagonist generation, five drugs were evaluated: chlorpheniramine, clemastine, diphenhydramine, hydroxyzine and tripolidine for the 1st-generation, and astemizole, cetirizine, fexofenadine, loratadine and terfenadine for the 2nd-generation. It was concluded that: 1. There is some slight, but ambiguous, evidence from epidemiological studies of a connection between antihistamine use and traffic collision rates.
    [Show full text]
  • Which Oral Antihistamines Are Safe to Use Whilst Breastfeeding?
    Medicines Q&As Q&A 206.2 Which oral antihistamines are safe to use whilst breastfeeding? Prepared by UK Medicines Information (UKMi) pharmacists for NHS healthcare professionals Before using this Q&A, read the disclaimer at www.ukmi.nhs.uk/activities/medicinesQAs/default.asp Date prepared: 13th April 2016 Background Oral antihistamines, which inhibit the effects of histamine at H1 receptors, have been classified as first generation (i.e. relatively sedating) or second generation (i.e. relatively non-sedating) (1). They are of potential value in the treatment of nasal allergies, particularly seasonal allergic rhinitis (hay fever) and vasomotor rhinitis. They may also be of some value in preventing urticaria and are used to treat urticarial rashes, pruritus, insect bites and stings, and are used in the treatment of drug allergies (2). First generation antihistamines cause sedation and this sedating activity is sometimes used to manage the pruritus associated with some allergies. There is little evidence that any one of the older, ‘sedating’ antihistamines is superior to another and patients vary widely in their response (2). Second generation antihistamines cause less sedation and psychomotor impairment than the first generation antihistamines possibly because they penetrate the blood brain barrier only to a slight extent (1). Table 1 summarises the licensed antihistamines available within the UK (2). Table1 Non-Sedating Antihistamines Sedating Antihistamines Cetirizine, loratadine, levocetirizine, Alimemazine, chlorphenamine, clemastine, desloratadine, acrivastine, bilastine, cyproheptadine, hydroxyzine, ketotifen, fexofenadine, mizolastine promethazine Answer According to the manufacturer’s data antihistamines are generally not advised in breastfeeding. However, this is not based on good evidence, but usually due to the lack of data and the possibility of transfer into breast milk.
    [Show full text]
  • 209089Orig1s000 209090Orig1s000
    CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: 209089Orig1s000 209090Orig1s000 CLINICAL REVIEW(S) CLINICAL REVIEW Application Type NDA (Rx to OTC switch) Application Number(s) 209-089 Xyzal Allergy 24 HR tablets 209-090 Xyzal Allergy 24 HR solution Priority or Standard Standard Submit Date(s) March 18, 2016 Received Date(s) March 31, 2016 PDUFA Goal Date January 31, 2017 Division / Office DPARP/ODE 2/OND Reviewer Name(s) Xu Wang, M.D., Ph.D. Review Completion Date December 9, 2016 Established Name Levocetirizine dihydrochloride Rx Trade Name Xyzal tablets/solution OTC Trade Name Xyzal Allergy 24HR tablets/solution Therapeutic Class Antihistamine Applicant UCB Inc. Formulation(s) tablets/solution Dosing Regimen ≥12 years: One tablet (5 mg) daily/10 mL solution (5 mg) daily; 1 6 – 11 years: /2 tablet (2.5 mg) daily/5 mL solution (2.5 mg) daily; 2 – 5 years: 2.5 mL solution (1.25 mg) daily Indication(s) Temporarily relieve these symptoms due to hay fever or other upper respiratory allergies: • running nose, • sneezing, • itchy, watering eyes, • itching of nose or throat Intended Population(s) Tablets: ≥6 years of age Solution: ≥2 years of age Template Version: March 6, 2009 Reference ID: 4025819 Clinical Review Xu Wang, M.D., Ph.D. NDA 209-089/NDA 209-090 Rx to OTC switch Xyzal Allergy 24HR (levocetirizine dihydrochloride) tablets/solution Table of Contents 1 RECOMMENDATIONS/RISK BENEFIT ASSESSMENT .........................................4 1.1 Recommendation on Regulatory Action ............................................................. 4 1.2 Risk Benefit Assessment .................................................................................... 4 2 INTRODUCTION AND REGULATORY BACKGROUND ........................................ 4 2.1 Product Information ............................................................................................ 4 2.2 Currently Available Treatments for Proposed Indications..................................
    [Show full text]